TECHWIRE 30
(CIX: WRAL30)  1,067.65  down arrow-3.49  (-0.33 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: Apple)  96.13  up arrow+0.53  (0.55 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NY: QUINTILES)  55.04  up arrow+0.11  (0.2 %)  Updated: 04:15 PM EDT, Aug 01 2014
(OP: BASF SE)  101.78  down arrow-1.47  (-1.42 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: BioCryst)  12.54  up arrow+0.02  (0.16 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: BioDelivery)  12.54  down arrow-0.21  (-1.65 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: CEMP)  9.30  up arrow+0.1  (1.09 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: Cisco Systems)  25.00  down arrow-0.23  (-0.91 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: Cree)  47.33  up arrow+0.1  (0.21 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: DARA)  1.31  up arrow+0.03  (2.34 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NY: EMC CORPORATION)  29.06  down arrow-0.24  (-0.82 %)  Updated: 04:15 PM EDT, Aug 01 2014
(NQ: Extreme Networks)  4.59  down arrow-0.11  (-2.34 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: FB)  72.36  down arrow-0.29  (-0.4 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NY: GLAXOSMITHKLINE)  48.03  down arrow-0.34  (-0.7 %)  Updated: 04:15 PM EDT, Aug 01 2014
(NQ: GOOG)  566.07  down arrow-5.53  (-0.97 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NY: IBM)  189.15  down arrow-2.52  (-1.31 %)  Updated: 04:15 PM EDT, Aug 01 2014
(NY: LH)  103.22  down arrow-0.47  (-0.45 %)  Updated: 04:15 PM EDT, Aug 01 2014
(OP: Lenovo Group)  27.38  up arrow+0.31  (1.15 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NY: MRK)  56.80  up arrow+0.06  (0.11 %)  Updated: 04:15 PM EDT, Aug 01 2014
(NQ: Microsoft Corp)  42.86  down arrow-0.3  (-0.7 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: NTAP)  38.54  down arrow-0.3  (-0.77 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NY: NOVARTIS AG)  86.90  down arrow-0.04  (-0.05 %)  Updated: 04:15 PM EDT, Aug 01 2014
(OP: Novozymes A/S)  48.12  down arrow-1.32  (-2.66 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NY: PFIZER)  28.86  up arrow+0.16  (0.56 %)  Updated: 04:15 PM EDT, Aug 01 2014
(NQ: Pozen)  7.09  down arrow-0.15  (-2.07 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NY: RED HAT)  58.39  up arrow+0.27  (0.46 %)  Updated: 04:15 PM EDT, Aug 01 2014
(NQ: BBRY)  9.30  down arrow-0.03  (-0.32 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: Salix)  134.88  up arrow+2.97  (2.25 %)  Updated: 05:20 PM EDT, Aug 01 2014
(NQ: SQI)  15.22  down arrow-0.17  (-1.1 %)  Updated: 05:20 PM EDT, Aug 01 2014

Posts tagged “GSK”

6:34 a.m. Tuesday

China to put GSK-hired investigators on trial Aug. 8

GSK China's web page  A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens.

July 24

GSK seeks regulator approval for malaria vaccine

Fighting malaria The experimental shot is the most advanced candidate vaccine for malaria but results from previous trials have been disappointing. Research published in 2012 showed the shot only reduced malaria cases by about 30 percent in babies aged six to 12 weeks, the target age for immunization.

Updated July 23

GSK sales, earnings slump; shares drop 5%; growth forecast slashed

GSK's HQ in London       Drug giant GlaxoSmithKline, hurt in part by a 20 percent decline in sales in China where the company is under criminal investigation, reports revenues and earnings that missed analysts' expectations on Wednesday. GSK also reduced its growth forecast for 2014 from as much as 8 percent to "basically similar" to 2013 and says it can't estimate what the financial impact could be from the China case.

July 23

CEO on the state of GSK: 'We're making significant progress'

Even with sales and profits declining sharply from a year ago, a cut in a growth forecast for this year and continuing legal issues resulting from a criminal investigation in China, GSK's chief executive officer Andrew Witty puts a positive spin on the state of the company in a video interview.

Top execs discuss GSK earnings, strategy Top execs discuss GSK earnings, strategy

July 15

GSK invests up to $25M in new drug manufacturing technology - in Pa., not N.C.

GlaxoSmithKline, which operates a huge drug manufacturing facility in Zebulon, is investing as much as $25 million to license a technology platform from a California firm as part of efforts to develop new drugs. But GSK isn't bringing the platform to N.C., at least initially.

GSK's R&D facility in RTP GSK's R&D facility in RTP

Updated July 14

China indicts U.S., British corporate investigators hired by GSK

China business   Chinese authorities have indicted British and American investigators hired by GlaxoSmithKline on charges of illegally obtaining and selling private information, state media reported Monday, as the Briton blamed the pharmaceutical company for misleading and using him.

Tags: GSK
July 7

US officials barred from trial of American in China linked to GSK investigation

GSK in China  U.S. diplomats will be barred from the trial in China of an American investigator for GlaxoSmithKline and her British husband who are charged with improperly selling personal information, according to a spokesman for the U.S. Embassy in Beijing.

Updated June 30

Premium Lock Sunday Times: Sex tape ignited GSK's China scandal

"Revealed: Sex tape blew open Glaxo's China bribery scandal," reads the big headline in the prestigious The Sunday Times says. A "clandestinely" filmed video of GSK's top China executive that was sent to GSK's CEO set off a company investigation that in turn ignited China's bribery probe against the drug giant, the paper says. In a statement to Reuters, GSK confirms the tape's existence.

Sunday Times report on its website Sunday Times report on its website

Updated June 4

Premium Lock GSK to pay $105M, including $2.5M to NC, for 'improper drug marketing'

GSK Headquarters      Drug giant GlaxoSmithKline will pay 44 states, including North Carolina, some $105 million to settle a case over improper drug marketing. North Carolina will receive $2.5 million. It's the third time since 2011 that GSK is paying N.C. as part of settlements for investigations.

June 2

Premium Lock Reports: GSK in $350M deal to develop cancer drugs

 GlaxoSmithKline has agreed to a deal worth more than $350 million with UK biotech company Adaptimmune to develop cancer drugs, the Financial Times reported on Monday.

Updated May 29

Premium Lock Even without a script, Bob Ingram can spin a crowd

The former Midwestern pharmaceutical sales rep "carried the bag" all the way to the office of CEO and chairman of GlaxoWellcome, and co-led its integration into today's GSK tells entrepreneurs they are the future as he reflects on a remarkable career.

Bob Ingram Bob Ingram

Updated May 28

Premium Lock GSK faces UK 'criminal investigation' into commercial practices

Drug giant GlaxoSmithKline disclosed Tuesday that the company is facing a "formal criminal investigation" by an agency of the British government. GSK already is under serious fire in China.

GSK's HQ in London       GSK's HQ in London

May 14

Premium Lock China accuses GSK executive of operating 'massive bribery network'

The executive, Mark Reilly, is accused of operating a "massive bribery network," a police official says at a news conference. He adds that the case had been handed over to prosecutors for formal indictment.

GSK China's web page  GSK China's web page

May 13

Premium Lock GSK to utilize genomics data, services from Metabolon

Triangle-based Metabolon, which recently struck a deal with DNA pioneer Craig Venter to help us find ways to live longer, has another high-profile partner: GlaxoSmithKline. The two neighbors disclosed a new collaboration agreement Tuesday.

Metabolon’s “Analytical Platform”: Metabolon’s “Analytical Platform”:

April 30

Premium Lock GSK's CEO remains bullish despite 18% drop in earnings

GSK's HQ in London       Sales were down but earnings were up and the forecast for growth remains on target, says GlaxoSmithKline CEO Andrew Witty about the drug giant's latest financial report.

April 23

Premium Lock Government contracts likely mean immunity for big Novartis vaccine plant

Plans for pharmaceutical giants Novartis, GlaxoSmithKline and Eli Lilly to swap business lines may have shaken up the stock market Tuesday, but work at a Novartis flu vaccine plant in Holly Springs hummed along, and local officials said they expect it to remain that way.

Novartis plant in Holly Springs Novartis plant in Holly Springs

Updated April 22

Premium Lock Glaxo CEO: Major deals to 'improve long-term earnings'

GSK's top executive Andrew Witty says the multiple deals announced early Tuesday with Novartis promise to deliver "broadly sustainable sourced sales growth and improve long-term earnings."

Andrew Witty   Andrew Witty

Updated April 22

Premium Lock Novartis swaps businesses with GSK, plans to sell Holly Springs plant

Novartis Two drug giants with major operations in the Triangle, Novartis and GlaxoSmithKline, are swapping businesses in two major deals. Meanwhile, Novartis plans to sell its huge Holly Springs plant in a separate deal and also strikes an agreement to sell its animal health business to Eli Lilly. No layoffs are planned, Novartis says.

Updated April 22

Premium Lock Novartis-GSK deals slide show: How they change Novartis

Drug giants Novartis and GlaxoSmithKline each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the Novartis presentation.

Novartis gains GSK's oncology portfolio Novartis gains GSK's oncology portfolio

Updated April 22

Premium Lock GSK-Novartis deals slide show: How they change GSK

Drug giants GlaxoSmithKline and Novartis each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the GSK presentation.

GSK's proposed new vaccine portfolio GSK's proposed new vaccine portfolio

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Scroll